

David D. Shepard, MD

Dr. Shepard, MD earned his Medical Degree from the Indiana University, School of Medicine in Indianapolis, Indiana. He completed his internal medicine residency at St. Vincent Hospital, in Indiana. His fellowship in hematology / oncology was completed at the Comprehensive Cancer Center of the University of Michigan. He is board certified in medical oncology and hematology. While actively providing patient care, he was an appointee to the Emory Breast Program Leadership Committee and the American Society of Hematology Trainee Council.

Dr. Shepard is recognized as one of the Top Doctors for excellence in Hematology and Oncology, in the Atlanta Magazine in 2020, 2021, 2022 and has been named a Castle Connolly Top Doctor of Atlanta for 2023. Dr. Shepard provides patient-centered care at NGOC's Vining's Cancer Center.

Undergraduate	BS, Major in Biology, May 2001 Morehouse College, Atlanta, Georgia
Medical Education	MD, June 2005 Indiana University, School of Medicine, Indianapolis, Indiana
Postdoctoral	RESIDENCY Straight Internal Medicine St. Vincent Hospital Indianapolis, Indiana, July 2005 - June 2008 FELLOWSHIP Hematology & Medical Oncology University of Michigan Ann Arbor, Michigan, July 2008 - June 2011
Investgator Training:	NCI Investigator Number: 50882 Protection of Human Subjects: Collaborative Institutional Training Initiative (CITI), 11/06/13 Good Clinical Practice: Collaborative Institutional Training Initiative (CITI), 11/04/13
Medical Licensure	State of Georgia, Physician License #066068, May 2011 National Provider Number (NPI): 1053588731
Board Certification	American Board of Internal Medicine, Internal Medicine, 2018 American Board of Internal Medicine, Medical Oncology, 2027 American Board of Internal Medicine, Hematology, 2027
Academic Appointments:	Emory at Decatur Breast Program Leadership Committee 12/2016-12/2019 Clinical Instructor Medical Education 2016-2020 American Society of Hematology Trainee Council, 2009
Work History:	Staff Physician, Hematology & Oncology Northwest Georgia Oncology Centers, PC Smyrna, Georgia

Emory at Decatur/Dekalb Medical Physician's Group

Atlanta Oncology Specialists
Decatur, Georgia
August 2015- October 2022

Private Practice, Medical Oncology & Hematology

Northwest Georgia Oncology Centers, PC
July 2011 – August 2015

Teacher, Remedial Math, Seventh Grade

Chute Middle School, District 65, Evanston, IL
June 2002 – August 2002

Teacher's Aide, Reading & Arithmetic, Third Grade

Atlanta Public Schools, Atlanta, GA
September 2000 – April 2001

Research Organizations:

National Cancer Institute, *06/13/13-present*

Professional Societies

Member, American Society of Clinical Oncology
Member, American Society of Hematology
Member, National Medical Association

Honors

Top Doctors, Recognized for Excellence in Hematology and Oncology,
Atlanta Magazine July 2020

Top Doctors, Recognized for Excellence in Hematology and Oncology,
Atlanta Magazine July 2021

Top Doctors, Recognized for Excellence in Hematology and Oncology,
Atlanta Magazine July 2022

Publications

Shepard D. Increasing Awareness – The Clinician Educator Track in
Academic Medicine. *The Hematologist*, 2010, 7:3.

Burwick N, **Shepard D.** ASH Makes a Positive Imprint on New Orleans High
School Students. *The Hematologist*, 2010, 7:1.

David W. Brown, MSPH, MSc, **Shepard D.**, Wayne H. Giles, MD, MSc, Kurt J.
Greenlund, PhD, and Janet B. Croft, PhD. (2005, Oct). Racial Differences in
the Use of Aspirin: An Important Tool for Preventing Heart Disease and
Stroke. *Journal of Ethnicity and Disease*, 15(4), 620 - 626.

Shepard D., DS and Urba S 2012. Esophageal Cancer. Worden F.
Tumor Board review. Guideline and case reviews in *Oncology*. (pp 61-
71). New York, NY: Demos Medical.

Abstracts:

Shepard D., Estes J, Griffith K, Kaminski M. Duration of Remission using I-
131 tositumomab in patients with B-cell lymphoma relapsing after autologous
stem cell transplant. ASCO Annual Meeting, abstract 2010.

Shepard D., Khort H, Rosenblat T, et al. Arsenic trioxide followed by
autologous stem cell transplant for patients with relapsed APL. ASCO Annual
Meeting Abstracts 2011 Abstract #6619

Bixby D, **Shepard D**, Rogers K, Avram AM, Kaminski MS. I-131
Tositumomab (Bexxar) can be safely given to lymphoma patients who are
intolerant of rituximab. ASCO Annual Meeting Abstracts 2011

Hematologic malignancies with a focus on lymphoma and myeloid leukemias

- Retrospective review on outcomes when I-131 tositumomab is utilized in indolent lymphoma relapsed post autologous stem cell transplant
- Retrospective multi-institutional study of outcomes in patients with relapsed acute promyelocytic leukemia salvaged with an arsenic containing regimen followed by autologous stem cell transplant while in second or greater molecular remission
- Concurrent JAK2 V617F and BCR/ABL1 positive myeloproliferative neoplasms, case studies on disease presentation, dominant phenotype, and response to tyrosine kinase inhibitors

Benign Hematology

- Retrospective analysis demonstrating that the hemolytic phenotype of sickle cell anemia predicts for an aggressive disease course in early adulthood with increasing incidence of end organ complications
-